Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Inovio Pharmaceuticals Inc (INO) vs Sociedad Quimica y Minera S.A. Common Stock (SQM) Price & Performance

Inovio Pharmaceuticals IncTrade
Sociedad Quimica y Minera S.A. Common StockTrade

Price performance (Past 24H)

Key statistics

Inovio Pharmaceuticals Inc vs Sociedad Quimica y Minera S.A. Common Stock — how do they compare? Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M), while Sociedad Quimica y Minera S.A. Common Stock trades at $63.86 (market cap $18.43B). The key difference: Sociedad Quimica y Minera S.A. Common Stock is far larger — about 164.3× Inovio Pharmaceuticals Inc's market cap, and Sociedad Quimica y Minera S.A. Common Stock pays a 3.76% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Sociedad Quimica y Minera S.A. Common Stock for 0 Days on average.

INOSQM
Market Cap
$112.19M$18.43B
Volume
3,201,278710,989
Sector
HealthBasic Materials
52-Week High
$2.65$95.31
52-Week Low
$0.66$40.77
Typical Hold Time
43 Days0 Days
Enterprise Value
$83.51M$19.29B
Dividend Yield
—3.76%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.

The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.

Sociedad Quimica y Minera S.A. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

INO
95% Buy5% Sell
Avg holding period · 43 Days
SQM
100% Buy0% Sell
Avg holding period · 0 Days

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO →

About Sociedad Quimica y Minera S.A. Common Stock

SQM is a mining and chemical company operating in northern Chile. Its businesses include lithium, iodine, specialty plant nutrition, potassium, solar salts, and industrial chemicals.

Read more on SQM →